FEBICO Shareholders’ Meeting Approves NT$1.5 Dividend per Share, Targeting Global Healthy Aging Opportunities with Brand Upgrade | EU & USDA Chlorella, Spirulina & Dietary Supplements Manufacturer | Far East Bio-Tec Co., Ltd.
Far East Bio-Tec Co., Ltd. (FEBICO, stock code: 6886) held its 2026 Annual General Shareholders’ Meeting on June 29, during which shareholders approved the company’s fiscal year 2025 financial statements and earnings distribution proposal.The meeting approved a dividend distribution of NT$1.5 per share, including a cash dividend of NT$0.5 and a stock dividend of NT$1.0, with an overall payout ratio of 79%. The dividend policy reflects FEBICO’s stable financial performance and demonstrates the company’s confidence in future business growth.In fiscal year 2025, FEBICO reported consolidated revenue of NT$401.697 million, net income after tax of NT$59.983 million, and earnings per share of NT$1.89. Compared with fiscal year 2024, consolidated revenue increased by 3.60%, net income after tax increased by 14.26%, and earnings per share increased by 10.53%, showing solid operating results. FEBICO is a Taiwan high-quality Organic Chlorella, Organic Spirulina, Chlorella growth factor(CGF), nattokinase, probiotics, DHA algae oil, superfoods manufacturer. With nearly 50 years of experience, FEBICO is committed to providing high-quality microalgae superfoods and health supplements to our global customers, along with exceptional service. Manufacturer of spirulina and chlorella (organic certified and natural) in Febico brand finish product, raw powder, bulk tablets, private labeling and OEM/ODM.
FEBICO Shareholders’ Meeting Approves NT$1.5 Dividend per Share, Targeting Global Healthy Aging Opportunities with Brand Upgrade
Far East Bio-Tec Co., Ltd. (FEBICO, stock code: 6886) held its 2026 Annual General Shareholders’ Meeting on June 29, during which shareholders approved the company’s fiscal year 2025 financial statements and earnings distribution proposal.
The meeting approved a dividend distribution of NT$1.5 per share, including a cash dividend of NT$0.5 and a stock dividend of NT$1.0, with an overall payout ratio of 79%. The dividend policy reflects FEBICO’s stable financial performance and demonstrates the company’s confidence in future business growth.
In fiscal year 2025, FEBICO reported consolidated revenue of NT$401.697 million, net income after tax of NT$59.983 million, and earnings per share of NT$1.89. Compared with fiscal year 2024, consolidated revenue increased by 3.60%, net income after tax increased by 14.26%, and earnings per share increased by 10.53%, showing solid operating results.
Chairman C.C. Chueh stated that as global population aging continues to accelerate, and as Taiwan has entered a super-aged society, demand for health management and nutritional supplementation is expected to continue growing. With its integrated technology platform covering microalgae R&D and cultivation, process development, and end-use applications, FEBICO will continue to strengthen its forward-looking technology strategy and market positioning in microalgae-based regenerative medicine.
The company is also actively expanding biomedical applications of microalgae while enhancing product development and channel deployment. In addition to strengthening its foundation in the Taiwan market and expanding its overseas presence, FEBICO is advancing its products and services from traditional health supplements into the precision care market. Through this strategy, the company aims to capture opportunities in the healthy aging industry, enhance brand competitiveness, increase market penetration, and strengthen future growth momentum.
In production and R&D, FEBICO operates its ESG microalgae cultivation site in Gaoshu, Pingtung. In addition, the company’s high-standard functional health food factory located in the Pingtung Agricultural Biotechnology Park has officially been completed. The new facility adds 1,200 ping of stainless steel, temperature-controlled production space and introduces automated production equipment, helping improve production efficiency and capacity in response to growing market demand.
Looking ahead, FEBICO will continue to develop precision health product lines and deepen channel partnerships. Driven by its broader health and precision wellness strategy, the company expects to build steady operational momentum.
In sustainability, FEBICO will continue to comply with domestic and international regulations and support government policies. The company is also introducing AI-powered process management and digital traceability systems to enhance production efficiency, quality management, and supply chain transparency.
At the same time, FEBICO is leveraging the unique characteristics of microalgae to promote a low-carbon green circular model. Through high-efficiency cultivation systems, carbon dioxide recycling, heat recovery, renewable energy, and related technologies, the company aims to move toward net-zero emissions while fulfilling its commitment to environmental sustainability and corporate social responsibility.
At the same time, FEBICO is leveraging the unique characteristics of microalgae to promote a low-carbon green circular model. Through high-efficiency cultivation systems, carbon dioxide recycling, heat recovery, renewable energy, and related technologies, the company aims to move toward net-zero emissions while fulfilling its commitment to environmental sustainability and corporate social responsibility.
Popular Products
FEBICO Shareholders’ Meeting Approves NT$1.5 Dividend per Share, Targeting Global Healthy Aging Opportunities with Brand Upgrade | EU & USDA Chlorella, Spirulina & Dietary Supplements Manufacturer | Far East Bio-Tec Co., Ltd.
Located in Taiwan since 1976, Far East Bio-Tec Co., Ltd. has been a chlorella, spirulina and dietary supplements manufacturer. Their main products, include Organic Spirulina, Organic Chlorella, Spirulina Natural, Chlorella Natural and Nutritional Supplements, which are produced with advanced fermentation facilities to produce high-quality nattokinase and spore-forming probiotics.
With nearly 50 years of experience, FEBICO is committed to providing high-quality microalgae superfoods and health supplements to our global customers, along with exceptional service. Manufacturer of spirulina and chlorella (organic certified and natural) in Febico brand finish product, raw powder, bulk tablets, private labeling and OEM/ODM.
FEBICO has been offering customers Naturland / EU and USDA-NOP certified chlorella, spirulina and dietary supplements, both with advanced technology and 47 years of experience, FEBICO ensures each customer's demands are met.